Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | BCL2 | P10415 | 1/20 | 0.38 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.38 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.38 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28516016 | 0.87 | ELANE (0.46) | ELANEMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL31108142 | 0.87 | ELANE (0.46) | ELANEMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL3077592 | 0.82 | BCL2 (0.45) | ELANEMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL11767518 | 0.80 | ELANE (0.48) | ELANEMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL27696416 | 0.79 | MEN1 (0.45) | MEN1KMT2AKDM4EUSP2GAA | |
| SCHEMBL30581210 | 0.79 | ELANE (0.44) | ELANEMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL4325209 | 0.79 | ELANE (0.43) | ELANEMEN1KMT2AKDM4EGAA | |
| SCHEMBL508302 | 0.78 | GABRA1 (0.53) | ELANEMEN1KMT2AKDM4EGAA | |
| SCHEMBL474923 | 0.78 | AKR1C3 (0.44) | ELANEMEN1KMT2AKDM4EUSP2 | |
| SCHEMBL170063 | 0.77 | AKR1C3 (0.50) | ELANEKDM4EGAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7592143-B2 | Methods of treating diseases responsive to induction of apoptosis and screening assays | CYTOVIA, INC. (US) | 2009-09-22 | — | — | US | disclosed |
| EP-1620564-A4 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | CYTOVIA INC (US) | 2008-03-12 | — | — | EP | disclosed |
| EP-1620564-A2 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | Cytovia, Inc. (US) | 2006-02-01 | — | — | EP | disclosed |
| US-20050004026-A1 | Methods of treating diseases responsive to induction of Apoptosis and screening assays | CYTOVIA, INC. | 2005-01-06 | — | — | US | disclosed |
| WO-2004094647-A2 | METHODS OF TREATING DISEASES RESPONSIVE TO INDUCTION OF APOPTOSIS AND SCREENING ASSAYS | CYTOVIA, INC. (US) | 2004-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004026-A1 | Methods of treating diseases responsive to induction of Apoptosis and screening assays | HEATR6, HEATR1, AIP | ELANE 4448/4885MEN1 4824/4885KMT2A 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.